Apomorphine and ropinirole data sharpen emetic choice in dogs

The debate over apomorphine versus ropinirole as a canine emetic is becoming more evidence-based, and less anecdotal. Two recent 2025 studies suggest the answer depends heavily on setting: in healthy dogs, ophthalmic ropinirole performed similarly to IV apomorphine for overall emetic success, while in emergency-clinic patients, ropinirole appeared slower and less dependable on first dose, with more minor adverse effects and more prolonged vomiting that needed rescue treatment. (public-pages-files-2025.frontiersin.org)

That matters because ropinirole changed the landscape when the FDA approved Clevor on June 16, 2020, as the first approved drug in the U.S. to induce vomiting in dogs. Before that, apomorphine was already widely used in practice, but as an extra-label option. The arrival of a labeled ophthalmic product gave clinicians a new route of administration and a product with defined prescribing parameters, including use in dogs 4.5 months and older and at least 1.8 kg. Those same age and weight thresholds also shaped enrollment in the 2025 emergency trial, which excluded younger or smaller dogs, dogs with apparent ocular disease, dogs with CNS or hepatic disease, cases where emesis was contraindicated such as caustic or volatile ingestions, and dogs that had already received antiemetics. (fda.gov)

The newer Frontiers study, published March 17, 2025, was a blinded randomized crossover trial in 24 healthy dogs. Investigators reported no significant difference in overall efficacy, with emesis induced successfully in 95.8% of dogs given apomorphine and 100% of dogs given ropinirole. But the practical differences were notable: apomorphine produced vomiting much faster, with a median onset of 1.18 minutes, compared with 8.85 minutes for ropinirole. Dogs given ropinirole also vomited more often, and the paper noted a higher incidence of ocular redness and protracted vomiting in that group. (public-pages-files-2025.frontiersin.org)

The emergency-setting study adds an important counterweight. As summarized by VetGirl’s review of the 2025 Journal of Veterinary Emergency and Critical Care paper by Reeves et al., this was a prospective randomized clinical trial conducted from October 2021 through March 2023 at two specialty referral hospitals and included 132 client-owned dogs after suspected or confirmed ingestion of a toxin or foreign body. Dogs were randomized to ropinirole eye drops (63 dogs) or IV apomorphine (69 dogs). If vomiting did not occur within 20 minutes, an identical second dose was given, and patients were monitored for 40 minutes. Cases included the kinds of ingestions emergency teams see every day: toxic foods such as chocolate, xylitol, grapes, and raisins; plants; medications; rodenticides and other poisons; and foreign material ranging from toys and cords to socks, towels, gloves, and underwear. According to the PubMed summary, ropinirole had a lower first-dose emetic success rate, a longer median time to first emetic event, more minor adverse events, and a higher frequency of protracted vomiting that required rescue therapy. Even without the full paper text available here, those details help explain why healthy-dog trial results may not translate cleanly to real-world emergency patients, where ingested material, stress, timing, and comorbidities complicate performance. (pubmed.ncbi.nlm.nih.gov)

Other background literature helps explain why practices may still see value in both drugs. FDA review of the Clevor field study found 95% of 100 client-owned dogs vomited within 30 minutes. The label allows a second dose if the dog does not vomit within 20 minutes, and the package insert reports prolonged vomiting lasting more than an hour in 8% of treated dogs. Meanwhile, pharmacy and toxicology guidance from the University of Illinois and ASPCApro notes that apomorphine generally acts faster, but may contribute more to CNS or respiratory depression, while ropinirole may be easier to administer and less likely to deepen CNS depressant effects. (fda.gov)

Expert commentary in accessible clinical guidance has been fairly consistent: neither drug is universally better, and case selection matters. ASPCApro frames apomorphine and ropinirole as both viable choices in dogs, while cautioning that ropinirole should not be used in patients with ocular disease. The University of Illinois comparison likewise emphasizes formulation, handling, and route as real-world differentiators, including the fact that apomorphine is commonly compounded and used extra-label, whereas ropinirole is a labeled ophthalmic product. (aspcapro.org)

Why it matters: For veterinary professionals, this is really a workflow and risk-stratification story. If a dog presents after a recent ingestion where every minute counts, the faster onset associated with IV apomorphine may still make it the more attractive option, especially in staffed emergency settings. If the goal is a labeled product with straightforward ophthalmic administration and potentially less concern about compounding or hazardous handling, ropinirole may be appealing. But the newer emergency data suggest teams should be prepared for slower onset, possible redosing, and management of prolonged vomiting when choosing ropinirole. That may affect triage protocols, technician time, antiemetic rescue planning, and conversations with pet parents about expectations in the treatment area. It also highlights the downstream importance of rescue antiemetics: Dechra recently announced FDA approval of Emeprev, an injectable maropitant bioequivalent for dogs and cats that the company says reduces injection pain in dogs because it contains benzyl alcohol and does not require refrigeration, with availability expected in early 2026. For clinics managing post-emesis nausea or prolonged vomiting, those practical handling and comfort features could be relevant. (public-pages-files-2025.frontiersin.org)

What to watch: The next question is whether additional comparative studies in actual toxicology and foreign-body patients, rather than healthy research dogs, support broader use of ropinirole or narrow it to selected cases; until then, many clinics will likely keep both agents in mind, using patient status, ocular health, CNS concerns, and urgency to guide the choice. A related practical watchpoint is how rescue-treatment options evolve as newer antiemetic products such as Emeprev reach clinics and potentially make management of prolonged vomiting a little easier operationally. (pubmed.ncbi.nlm.nih.gov)